Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease

Soluble RAGE (sRAGE) serum level could be a biomarker for atherosclerosis and subsequent diseases such as cardiovascular disease (CVD). Therefore, we wanted to investigate whether peripheral sRAGE level is associated with new cardiovascular events among patients with CVD using the Cox's regress...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2017-11, Vol.266, p.234-239
Main Authors: Reichert, Stefan, Triebert, Ulrike, Santos, Alexander Navarrete, Hofmann, Britt, Schaller, Hans-Günter, Schlitt, Axel, Schulz, Susanne
Format: Article
Language:English
Subjects:
Aged
Angiography
Biomarkers - blood
Cardiovascular disease
Cardiovascular Diseases - blood
Cardiovascular Diseases - diagnostic imaging
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - mortality
Chi-Square Distribution
Enzyme-Linked Immunosorbent Assay
Female
Germany - epidemiology
Humans
Incidence
Ischemic Attack, Transient - blood
Ischemic Attack, Transient - epidemiology
Kaplan-Meier Estimate
Longitudinal Studies
Male
Middle Aged
Multivariate Analysis
Myocardial Infarction - blood
Myocardial Infarction - epidemiology
New cardiovascular events
Predictive Value of Tests
Prognosis
Proportional Hazards Models
Receptor for Advanced Glycation End Products - blood
Risk Factors
sRAGE
Stroke - blood
Stroke - epidemiology
Time Factors
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Soluble RAGE (sRAGE) serum level could be a biomarker for atherosclerosis and subsequent diseases such as cardiovascular disease (CVD). Therefore, we wanted to investigate whether peripheral sRAGE level is associated with new cardiovascular events among patients with CVD using the Cox's regression analysis. In this three-year longitudinal cohort study, 1002 in-patients with angiographically proven CVD were included. In 933 patients, sRAGE levels were determined by a commercial available ELISA kit at the time of baseline examination. The combined endpoint was defined as myocardial infarction, stroke/TIA (non-fatal, fatal), and cardiovascular death. For risk analysis, sRAGE values were distributed in quartiles. For generation of adjusted hazard ratios (HR), other risk factors for CVD, such as age, gender, current smoking, body mass index, diabetes, hypertension, dyslipoproteinemia, family history of CVD, severe periodontitis, serum levels for C-reactive protein and interleukin-6, were recorded. 886 patients completed the 3-year follow-up. The overall incidence of the combined endpoint was 16%. Patients with sRAGE levels >838.19 pg/ml (fourth quartile) had the highest incidence of recurrent CVD events (24.9% versus 13.1%, p 838.19 pg/ml had the highest incidence of recurrent CVD events (24.9% versus 13.1%, p 
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2017.08.015